Companies that own Genfit S.A.
Heights Capital Management, Inc.
1,317,005
4.23%
0
1.03%
12/31/2017
The Vanguard Group, Inc.
730,025
2.34%
26,483
0%
07/31/2018
OppenheimerFunds, Inc.
449,840
1.44%
0
0.01%
02/28/2018
BlackRock Fund Advisors
335,364
1.08%
231
0%
09/06/2018
Norges Bank Investment Management
334,841
1.07%
-89,295
0%
12/31/2017
Alken Asset Management Ltd.
232,396
0.75%
907
0.15%
12/31/2017
Syquant Capital SAS
213,142
0.68%
43,264
0.73%
06/30/2017
JPMorgan Asset Management (UK) Ltd.
188,842
0.61%
0
0%
05/31/2018
AXA Investment Managers UK Ltd.
175,174
0.56%
0
0.02%
02/28/2018
Rhenman & Partners Asset Management AB
153,369
0.49%
-35,221
0.32%
12/31/2017
| Address |
Parc Eurasante
Loos Nord-Pas-de-Calais 59120
France
|
|
Employees
|
- |
| Website |
http://www.genfit.com |
| Updated |
07/08/2019 |
| Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. Its research and development efforts are focused on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. |
